Drug Discovery Stories: From Bench to Bedside, Volume 3 presents a collection of cases on the development of highly successful pharmaceuticals. The coverage of chapters in the book include the structural biology and biological functions of the targets of interest, the identification of hit compounds, hit-to-lead optimization, binding mode of the key compounds with the target of interest, key biological and PK data of lead compounds, clinical results if any, other candidate compounds in preclinical and clinical stage against the same target, and other relevant points in the journey to develop the drug. Chapters in this volume in the Drug Discovery Stories series include a discussion of technological innovations in drug discovery, the impact of AI and Machine Learning, and then move on to discuss drugs like Landiolol, Deuruxolitinib, Berdazimer sodium, Cefepime, Aprocitentan, Givinostat, Vadadustat, Danicopan, Tovorafenib, Lazertinib, Journavx, Symbravo, Grafapex, Alyftrek, and Tryngolza. A final chapter provide conclusions on all cases presented in the book.
Drug Discovery Stories: From Bench to Bedside, Volume 3 accurately reflects the current advancements in drug discovery by sharing the path researchers took that led them to create these impactful drugs. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
- Describes the drug discovery stories of different blockbuster drugs
- Provides insights into the drug discovery journey for the specific drugs presented
- Covers recently approved drugs of great therapeutic potential
